Acer Therapeutics Inc.

Acer Therapeutics Inc. (https://acertx.com/) is a pharmaceutical company. The Company is focused on the acquisition, development, and commercialization of therapies for serious rare and life-threatening diseases. The Company's pipeline includes four programs: ACER-001, EDSIVO, ACER-801 and ACER-2820. The ACER-001 (Sodium phenylbutyrate) for the treatment of various inborn errors of metabolism, including urea cycle disorders (UCDs) and Maple Syrup Urine Disease (MSUD). The EDSIVO (celiprolol) is a selective adrenergic modulator (SAM) for the treatment of vascular Ehlers-Danlos syndrome (vEDS) in patients with a confirmed type III collagen (COL3A1) mutation. The ACER-801 (osanetant) is a non-peptide tachykinin NK3 receptor antagonist for the treatment of induced Vasomotor Symptoms (iVMS). The ACER-2820 (emetine), a host-directed therapy against a variety of infectious diseases, including COVID-19.

• Acer Therapeutics Inc.